Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more
Chengdu Easton Biopharmaceuticals Co Ltd - Asset Resilience Ratio
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has an Asset Resilience Ratio of 27.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Chengdu Easton Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥981.76 Million | 27.59% |
| Total Liquid Assets | CN¥981.76 Million | 27.59% |
Asset Resilience Insights
- Very High Liquidity: Chengdu Easton Biopharmaceuticals Co Ltd maintains exceptional liquid asset reserves at 27.59% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Chengdu Easton Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chengdu Easton Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Chengdu Easton Biopharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.30% | CN¥452.35 Million | CN¥3.40 Billion | -8.86pp |
| 2023-12-31 | 22.16% | CN¥741.78 Million | CN¥3.35 Billion | +5.05pp |
| 2022-12-31 | 17.11% | CN¥516.36 Million | CN¥3.02 Billion | +0.76pp |
| 2021-12-31 | 16.35% | CN¥453.84 Million | CN¥2.78 Billion | -6.17pp |
| 2020-12-31 | 22.52% | CN¥570.00 Million | CN¥2.53 Billion | +21.34pp |
| 2013-12-31 | 1.18% | CN¥3.00 Million | CN¥254.86 Million | -- |